A cystatin C–based blood test may provide a more reliable way to monitor kidney function in children and young adults with SCD, a study found.

The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD).

Q4 2025 Earnings Call March 3, 2026 4:30 PM ESTCompany ParticipantsPatrick Soon-Shiong - Founder, Executive Chairman and ...

By Hugo Francisco de Souza A sweeping Lancet review reveals how modern incretin-based drugs are reshaping treatment for ...